Avadel Pharmaceuticals Announces First Patient Dosed in Open-Label Extension/Switch Study of Investigational Once-Nightly FT218 as a Potential Treatment for Excessive Daytime Sleepiness an...
Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL)
Last avadel pharmaceuticals plc - american depositary shares each representing one ordinary share earnings: 3/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
avadel.com
Company Research
Source: GlobeNewswire
Clinical study to enroll 250 patients from sites that participated in the REST-ON studyStudy to examine the long-term safety and maintenance of efficacy in patients, and evaluate dosing and preference for patients switching from twice-nightly sodium oxybate to once-nightly FT218 DUBLIN, Ireland, July 13, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate, today announced that the first patient has been dosed at a Florida Research Institute initiating an open-label extension (OLE)/switch study of FT218 as a potential treatment for excessive daytime sleepiness and cataplexy in patients with narcolepsy. “Narcolepsy is a rare neurological sleep disorder with limited treatment options. We were encouraged by the positive Phase 3 data from the REST-ON study that evaluated FT218 as a potential treatment for excessive daytime sleepiness and cataplexy in patients with n
Show less
Read more
Impact Snapshot
Event Time:
AVDL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AVDL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AVDL alerts
High impacting Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share news events
Weekly update
A roundup of the hottest topics
AVDL
News
- Avadel Pharmaceuticals: Robust Launch Of Lumryz And Eased Litigation Overhang [Seeking Alpha]Seeking Alpha
- Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Avadel Pharmaceuticals plc (NASDAQ: AVDL) had its price target raised by analysts at Craig Hallum from $20.00 to $22.00. They now have a "buy" rating on the stock.MarketBeat
- Avadel Pharmaceuticals plc (NASDAQ: AVDL) had its price target raised by analysts at Piper Sandler from $18.00 to $23.00. They now have an "overweight" rating on the stock.MarketBeat
- Avadel Pharmaceuticals plc (NASDAQ: AVDL) had its price target raised by analysts at Oppenheimer Holdings Inc. from $27.00 to $29.00. They now have an "outperform" rating on the stock.MarketBeat
AVDL
Earnings
- 11/8/23 - Miss
AVDL
Sec Filings
- 3/4/24 - Form 8-K
- 3/4/24 - Form 8-K
- 3/4/24 - Form 4
- AVDL's page on the SEC website